Investing.com -- Genus (LON: GNS ), the British animal genetics company, saw its stock price leap nearly 30% to 2,055p, making it the leading gainer on the FTSE mid-cap index.

This significant increase came after the U.S. Food and Drug Administration (FDA) approved a gene-edited pig, known as the PRRS resistant pig (PRP), for use in the U.S. food supply chain.

Genus specializes in the study and manipulation of animal genetics, and the FDA’s approval of their PRP gene-edited pig marks a significant milestone for the company.

The PRP pig has been genetically modified to resist the Porcine Reproductive and Respiratory Syndrome (PRRS), a disease that can cause significant losses in the pig farming industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.